Evidence· July 5, 2026 · 17 min read
Topic
Generics
ANDA strategy, Paragraph IV risk, therapeutic equivalence, supply concentration, and price erosion.
Evidence· July 4, 2026 · 16 min read
Bisphosphonates in FAERS: 191,890 adverse-event reports by the numbers
Policy· June 30, 2026 · 18 min read
FDA Market Exclusivity by the Numbers: Exclusivity and GAIN Registry Analysis
By Ran Chen#Orange Book#Generics#Generic Entry
Generics· June 29, 2026 · 18 min read
Generic Xarelto Entry: Orange Book Patents and NADAC Price Erosion
By Ran Chen#Generics#Orange Book#Generic Entry
Policy· June 28, 2026 · 19 min read
How to Read an FDA REMS: ETASU, Shared vs. Single REMS, and the Patent Dance
By Ran Chen#REMS#Generics#FDA Approval
Generics· June 27, 2026 · 18 min read
Generic Aubagio Market: ANDA Litigation Settlements and NADAC Pricing
By Ran Chen#Generics#FDA Approval#Market Access
Generics· June 27, 2026 · 17 min read
Generic Latuda Market: ANDA Exclusivity Settlements and NADAC Pricing
By Ran Chen#Generics#FDA Approval#Market Access
Generics· June 27, 2026 · 18 min read
Generic Restasis: Complex Ophthalmic Barriers and NADAC Pricing
By Ran Chen#Generics#FDA Approval#Ophthalmology
Generics· June 26, 2026 · 22 min read
Generic Revlimid REMS Launch: Lenalidomide ANDA Entry and NADAC Absence
By Ran Chen#Generics#Orange Book#Oncology
Generics· June 26, 2026 · 21 min read
Generic Tecfidera: Dimethyl Fumarate Patent Settlements and NADAC Erosion
By Ran Chen#Generics#Orange Book#PBM